Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models

VR ROZADOS.; LI. HINRICHSEN; MM BINDA; SI GERVASONI; P MATAR; RD BONFILAND; OG SCHAROVSKY

ONCOLOGY REPORTS

SPANDIDOS PUBL LTD

Lugar: Atenas; Año: 2008 vol. 19 p. 1205 - 1211

1021-335X

Despite its effectiveness as an antineoplastic drug, doxorubicin (DOX) is usually associated with cardiotoxicity. Lovastatin (LOV), a hypolipidemic agent used in the clinic, has been demonstrated to have antitumoral and antimetastatic effects in murine models. Since both agents arrest tumor cells in different phases of the cell cycle and induce apoptosis, the goal of this study was to examine the efficacy of combination therapy with LOV and low doses of DOX, in an attempt to obtain an improved antitumoral effect devoid of toxicity, using a rat B-cell lymphoma and a mouse mammary tumor. In both models, the combined treatment showed a synergistic antitumoral effect, which is mainly ascribed to an increased apoptotic response elicited by LOV/DOX combination than either agent alone. The therapeutic benefit demonstrated by the combination treatment is further emphasized by the lack of toxicity.